Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ipatasertib in Combination with Docetaxel for the Treatment of Non-small Cell Lung Cancer

Trial Status: active

This phase II trial evaluates ipatasertib in combination with docetaxel for the treatment of small-cell lung cancer that has spread to other parts of the body (advanced/metastatic) and which has failed initial treatments. Ipatasertib is an enzyme inhibitor that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and can enhance the therapeutic effect of chemotherapy drugs such as docetaxel, which stops the growth of cancer cells either by killing the cells, stopping them from dividing, or stopping them from spreading.